Acurx Pharmaceuticals, Inc.

ACXP · NASDAQ

Acurx is a no-revenue antibiotic developer with a Phase 3-ready CDI lead asset, a new recurrent-CDI pilot plan, repeated equity financing, and explicit going-concern pressure. The question is whether ibezapolstat gets financed into proof before dilution becomes the main story.

Follow Add to Watchlist Ask Question

NASDAQ ACXP Coverage Bootstrap Biotechnology Antibiotics Infectious Disease

Latest ReportMay 14, 2026Acurx: the CDI antibiotic bet racing a cash clockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.